Pine Brook, NJ and St. Louis, MO, USA: January 22, 2013 –Refine Technology, LLC (Refine), the developer
and worldwide supplier to the biotech industry of the ATF™ System, a best-in-class cell retention device, and
Gallus BioPharmaceuticals, LLC (Gallus), the industry leading contract bulk biopharmaceuticals manufacturer,
today announced a collaboration to optimize continuous cell culture processes.
Gallus has already developed deep experience of Refine’s ATF System as the leading CMO in perfusion
technology. Gallus uses the ATF System to manufacture a commercial antibody, StelaraTM, for J&J, which is
distributed globally. Gallus looks to build upon this collaboration with Refine to expand the use of ATF System
in perfusion, concentrated high cell density processes, and disposable processes.
“We are looking forward to deepening our involvement with Gallus, who are a skilled and flexible partner to
work with,” stated Jerry Shevitz, President of Refine. “Many biopharmaceutical companies, both small and
large, desire to move into high cell density and continuous production methods using our ATF System.
Together, Refine and Gallus will be able to help these companies achieve their goals and deliver more robust
quality and lower cost bioprocesses, building on the Gallus Center of Excellence for continuous processing for
mammalian cell culture.
“With experience of developing over 40 molecules during a 26 year site history, combined with a decade of
commercial manufacturing history, Gallus is strongly positioned to support clients to exploit the advantages of
the ATF System in process development, clinical supply and commercial licensure for their products” said
Mark R. Bamforth, President & CEO at Gallus. “We are excited to expand Gallus’ leading technology
partnerships by collaborating with Refine and their best-in-class technology.”
About Refine Technology
Refine Technology develops and commercializes equipment for the enhancement of cell culture processes.
Its ATF System, which scales for use in the laboratory through to commercial manufacturing, has a range of
uses from simple culture maintenance and perfusion, to generation of “extreme” cultures, to complex vaccine
manufacturing. Refine Technology is dedicated to quality, customer support and providing solutions to a
rapidly evolving biopharmaceutical industry. Based in New Jersey, USA, Refine Technology distributes and
services its products worldwide through its network of highly trained sales and support personnel.
About Gallus Biopharmaceuticals
Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract
services to its clients. The firm, based in St. Louis, Mo., was established in 2010 and acquired a world-class
commercial biopharmaceutical manufacturing facility and workforce from Johnson & Johnson/Centocor
division in 2011. In addition to process development and clinical supply services, Gallus currently produces
two commercial products that are distributed globally. The St. Louis facility has been inspected by every major
regulatory body worldwide. For additional information on biopharmaceutical contract development and
manufacturing services, visit www.gallusbiopharma.com, email email@example.com or call directly at
Chief Commercial Officer
Gallus BioPharmaceuticals, LLC
Tel.: +1 314-733-3914
VP Business Development, Refine Technology, LLC
US Cell: +1 732 993 3003
EU Mob.: +46 76 256 5114